Moving from conventional to adaptive risk stratification for oropharyngeal cancer
Oropharyngeal cancer (OPC) poses a complex therapeutic dilemma for patients and oncologists alike, made worse by the epidemic increase in new cases associated with the oncogenic human papillomavirus (HPV). In a counterintuitive manner, the very thing which gives patients hope, the high response rate of HPV-associated OPC to conventional chemo-radiation strategies, has become one of the biggest challenges for the field as a whole. It has now become clear that for ~30-40% of patients, treatment intensity could be reduced without losing therapeutic efficacy, yet substantially diminishing the acute and lifelong morbidity resul...
Source: Frontiers in Oncology - March 14, 2024 Category: Cancer & Oncology Source Type: research
Neoadjuvant ipilimumab plus nivolumab therapy as a potential organ preservation strategy in mucosal melanoma: case report
We present two cases of mucosal melanoma, each with potential regional dissemination, who were treated with neoadjuvant immunotherapy with minimal toxicity. Both patients were closely monitored and achieved radiologic and pathologic complete responses. These patients were able to avoid radical surgery and related functional consequences. Both patients remain recurrence-free with protracted follow-up. The potential usefulness of neoadjuvant immunotherapy as an organ preservation strategy in mucosal melanoma deserves further evaluation in prospective clinical trials. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 14, 2024 Category: Cancer & Oncology Source Type: research
The fertility-sparing treatment and outcome of epithelioid trophoblastic tumor isolated to lung: a case report and review literature
ConclusionOur case highlights the efficacy of fertility-sparing surgery for isolated ETT in lungs. The surgical management of pulmonary isolated ETT could be individualized under long-term supervision. Sporadic reports on the favorable outcome of extra-uterine ETT with fertility-sparing surgery were described in the last decades. The safety of this surgical strategy might be warranted only if enough reliable data is accumulated. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 14, 2024 Category: Cancer & Oncology Source Type: research
Multimodal data integration for predicting progression risk in castration-resistant prostate cancer using deep learning: a multicenter retrospective study
ConclusionThe integration of multimodal data effectively improves the prediction of risk for the progression of PCa to CRPC. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 14, 2024 Category: Cancer & Oncology Source Type: research
Exploration of the molecular biological mechanisms and review of postoperative radiotherapy cases in tenosynovial giant cell tumors
In this study, we first reviewed the medical records of two female TGCT patients who had undergone radiotherapy. Then, by combining bioinformatics and machine learning, we interpreted the pathogenesis of TGCT and its associations with other diseases from multiple perspectives. Based on a deep analysis of the case data, we provided empirical support for postoperative radiotherapy in TGCT patients. Additionally, our further analysis revealed the signaling pathways of differentially expressed genes in TGCT, as well as its potential associations with osteoarthritis and synovial sarcomas. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 14, 2024 Category: Cancer & Oncology Source Type: research
Antibody-drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis
In 2020, bladder cancer ascended to the 10th most common malignancy and is chiefly a subtype of urothelial carcinoma. For patients with metastatic urothelial carcinoma, the standard first-line treatment remains platinum-based chemotherapy, with immunotherapy serving as an alternative in cases of programmed death ligand 1 expression. However, treatment options become limited upon resistance to platinum and programmed death 1 or programmed death ligand 1 agents. Since the FDA's approval of Enfortumab Vedotin and Sacituzumab Govitecan, the therapeutic landscape has expanded, heralding a shift towards antibody–drug conjugate...
Source: Frontiers in Oncology - March 14, 2024 Category: Cancer & Oncology Source Type: research
Corrigendum: LncRNA-AC02278.4 is a novel prognostic biomarker that promotes tumor growth and metastasis in lung adenocarcinoma
(Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 13, 2024 Category: Cancer & Oncology Source Type: research
Gemcitabine combination therapies induce apoptosis in uterine carcinosarcoma patient-derived organoids
In conclusion, for the UCS1 patient-derived tumor cells, gemcitabine combinations were more effective than carboplatin/paclitaxel. Our data support the use of PDOs to predict responses to second-line chemotherapy. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 13, 2024 Category: Cancer & Oncology Source Type: research
Corrigendum: Glioblastoma survival is associated with distinct proteomic alteration signatures post chemoirradiation in a large-scale proteomic panel
(Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 13, 2024 Category: Cancer & Oncology Source Type: research
Emerging role of m6A modification in ovarian cancer: progression, drug resistance, and therapeutic prospects
Ovarian Cancer (OC) ranks as a prominent contributor to mortality among female reproductive system associated cancers, particularly the prevalent subtype epithelial Ovarian Cancer (EOC). Despite advancements in treatment modalities, the prognosis for OC patients remains grim due to limitation of current therapeutic methodology such as high cytotoxicity of chemotherapeutic agents and tumor relapse making existing chemotherapy ineffective. Recognizing the limitations of a broad-spectrum approach to treating OC, a shift toward targeted therapies aligning with unique molecular features is imperative. This shift stems from an i...
Source: Frontiers in Oncology - March 13, 2024 Category: Cancer & Oncology Source Type: research
Unraveling trajectories from aplastic anemia to hematologic malignancies: genetic and molecular insights
ConclusionThis study highlights the genetic dynamics in the progression from AA to hematologic malignancy. Monosomy 7’s prevalence and the occurrence of PTPN11 mutations suggest predictive and prognostic significance. Clonal evolution underscores the complexity of disease progression. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 13, 2024 Category: Cancer & Oncology Source Type: research
Military environmental exposures and risk of breast cancer in active-duty personnel and veterans: a scoping review
ConclusionsWomen are the fastest growing population within the military, and breast cancer poses a unique risk to women Veterans who were affected by MEE during their service. Unfortunately, the literature on MEE and breast cancer is mixed and limited, in part due to the Healthy Soldier Paradox and poor classification of exposure(s). (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 13, 2024 Category: Cancer & Oncology Source Type: research
Mapping breast and prostate cancer in the Brazilian public health system: study protocol of the Onco-Genomas Brasil
DiscussionThis trial will contribute to the construction of a robust database that should provide a better understanding of the genomic profile of patients with breast and prostate cancer in Brazil. Considering the miscegenation of the Brazilian population, knowledge generated from these data will have implications for future studies of this specific population.Clinical trial registration[clinicaltrial.gov], identifier [NCT05306600] (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 13, 2024 Category: Cancer & Oncology Source Type: research
Patient-reported outcomes in Hodgkin lymphoma trials: a systematic review
DiscussionsOnly one-third of RCTs in HL report PROs as an outcome and only half present the outcome in subsequent publications, showcasing the underreporting of PROs in trials. Disease-specific PROMs are underutilized in the assessment of QoL in HL patients. Guidance on the assessment of PROs is needed to inform on comprehensive outcomes important to patients.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=391552, identifier CRD42023391552. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 13, 2024 Category: Cancer & Oncology Source Type: research
Editorial: Methods in radiation oncology
(Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 13, 2024 Category: Cancer & Oncology Source Type: research
